LEAD Program
Our lead compound: TTX-01 (CDDO 2P-Im)
TTX-01 is a fourth-generation synthetic triterpenoid designed as an oral, brain-penetrant therapy that complements existing standard of care.
Unprecedented Potency
Preclinical studies show TTX-01 is the most powerful triterpenoid developed to date with data demonstrating that it is 1000X more potent than earlier compounds and superior to leading NLRP3 inhibitors like MCC950.
Proven Potential in Brain Disease
In neurodegenerative disease models, data demonstrate that TTX-01 crosses the blood-brain barrier and reduces Alzheimer’s pathology including amyloid plaques, while protecting neurons from inflammatory damage.
In brain cancer models, data demonstrate that TTX-01 overcomes resistance to standard chemotherapy (TMZ), enhances radiation effectiveness, and significantly delays tumor progression in glioblastoma.
next generation: TTX-02 (CDDO 3P-Im)
TTX-02 builds on TTX-01’s success as it is designed to enhance brain penetration and complementary therapeutic activity. Currently in optimization, this compound is being refined for specific neurodegenerative applications with improved selectivity and extended duration of action.
Future Pipeline Assets
We’re developing sixteen fluorinated analogs including eight based on TTX-01 and eight on TTX-02. Each are designed to enhance specific therapeutic properties. These next-generation compounds aim to improve brain penetration, increase selectivity, and optimize oral dosing while maintaining our compounds’ proven safety profile.
Through systematic optimization, we’re building a robust pipeline that addresses the evolving needs of patients with brain diseases.